ADRA2A and IRX1 are putative risk genes for Raynauds … – Nature.com

Hughes, M. et al. Prediction and impact of attacks of Raynauds phenomenon, as judged by patient perception. Rheumatology 54, 14431447 (2015).

Article PubMed Google Scholar

De Angelis, R., Salaffi, F. & Grassi, W. Health-related quality of life in primary Raynaud phenomenon. J. Clin. Rheumatol. 14, 206210 (2008).

Article PubMed Google Scholar

Fbin, B., Csiki, Z. & Bugn, A. Raynaudszindrms betegek letminsgnek jellemzi. Orv. Hetil. 159, 636641 (2018).

Article PubMed Google Scholar

Wigley, F. M. & Flavahan, N. A. Raynauds phenomenon. N. Engl. J. Med. 375, 556565 (2016).

Article CAS PubMed Google Scholar

Rirash, F. et al. Calcium channel blockers for primary and secondary Raynauds phenomenon. Cochrane Database Syst. Rev. 2017, (2017).

Belch, J. et al. ESVM guidelinesthe diagnosis and management of Raynauds phenomenon. Vasa 46, 413423 (2017).

Article PubMed Google Scholar

Su, K. Y. C. et al. Vasodilators for primary Raynauds phenomenon. Cochrane Database Syst. Rev. 2021, (2021).

Ennis, D., Ahmad, Z., Anderson, M. A. & Johnson, S. R. Botulinum toxin in the management of primary and secondary Raynauds phenomenon. Best Pract. Res. Clin. Rheumatol. 35, 101684 (2021).

Article PubMed Google Scholar

Cherkas, L. F. et al. Heritability of Raynauds phenomenon and vascular responsiveness to cold: a study of adult female twins. Arthritis Care Res. 57, 524528 (2007).

Article CAS Google Scholar

Hur, Y. M. et al. Feeling of cold hands and feet is a highly heritable phenotype. Twin Res. Hum. Genet. 15, 166169 (2012).

Article PubMed Google Scholar

Smyth, A. E., Hughes, A. E., Bruce, I. N. & Bell, A. L. A case-control study of candidate vasoactive mediator genes in primary Raynauds phenomenon. Rheumatology 38, 10941098 (1999).

Article CAS PubMed Google Scholar

Shemirani, A. H. et al. Polymorphism of clotting factors in Hungarian patients with Raynauds. Blood Coagul. Fibrinolysis 22, 5659 (2011).

Article CAS PubMed Google Scholar

Susol, E. et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynauds phenomenon. Arthritis Rheum. 43, 16411646 (2000).

Article CAS PubMed Google Scholar

Munir, S., Freidin, M. B., Brain, S. & Williams, F. M. K. Association of Raynauds phenomenon with a polymorphism in the NOS1 gene. PLoS ONE 13, 18 (2018).

Article Google Scholar

Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203209 (2018).

Article ADS CAS PubMed PubMed Central Google Scholar

Zhang, X. & Sun, Y. The predictive role of adra2a rs1800544 and htr3b rs3758987 polymorphisms in motion sickness susceptibility. Int. J. Environ. Res. Public Health 18, 151 (2021).

Chotani, M. A., Flavahan, S., Mitra, S., Daunt, D. & Flavahan, N. A. Silent (2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am. J. Physiol.Hear. Circ. Physiol. 278, 10751083 (2000).

Article Google Scholar

Freedman, R. R., Sabharwal, S. C., Desai, N., Wenig, P. & Mayes, M. Increased adrenergic responsiveness in idiopathic Raynauds disease. Arthritis Rheum. 32, 6165 (1989).

Article CAS PubMed Google Scholar

Freedman, R. R., Moten, M., Migaly, P. & Mayes, M. Coldinduced potentiation of 2adrenergic vasoconstriction in primary Raynauds disease. Arthritis Rheum. 36, 685690 (1993).

Article CAS PubMed Google Scholar

Buniello, A. et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005D1012 (2019).

Article CAS PubMed Google Scholar

Ochoa, D. et al. Open Targets Platform: supporting systematic drug-target identification and prioritisation. Nucleic Acids Res. 49, D1302D1310 (2021).

Article CAS PubMed Google Scholar

GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 13181330 (2020).

Kster, M. M. et al. Epigenetic inactivation of the tumor suppressor IRX1 occurs frequently in lung adenocarcinoma and its silencing is associated with impaired prognosis. Cancers (Basel). 12, 120 (2020).

Article Google Scholar

Aoki, A. et al. SNPs on chromosome 5p15.3 associated with myocardial infarction in Japanese population. J. Hum. Genet. 56, 4751 (2011).

Article CAS PubMed Google Scholar

Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 14151424 (2021).

Article CAS PubMed Google Scholar

Koyama, S. et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat. Genet. 52, 11691177 (2020).

Article CAS PubMed Google Scholar

Vuckovic, D. et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell 182, 12141231.e11 (2020).

Article CAS PubMed PubMed Central Google Scholar

Chen, M. H. et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell 182, 11981213.e14 (2020).

Aragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. medRxiv https://doi.org/10.1101/2021.05.24.21257377 (2021).

Finer, S. et al. Cohort Profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. Int. J. Epidemiol. 49, 2021i (2020).

Article PubMed Google Scholar

OConnor, L. J. & Price, A. L. Distinguishing genetic correlation from causation across 52 diseases and complex traits. Nat. Genet. 50, 17281734 (2018).

Article PubMed PubMed Central Google Scholar

Licata, L. et al. SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update. Nucleic Acids Res. 48, D504D510 (2020).

CAS PubMed Google Scholar

Edwards, J. M., Phinney, E. S., Taylor, L. M., Keenan, E. J. & Porter, J. M. 2-Adrenergic receptor levels in obstructive and spastic Raynauds syndrome. J. Vasc. Surg. 5, 3845 (1987).

CAS PubMed Google Scholar

Flavahan, N. A. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat. Rev. Rheumatol. 11, 146158 (2015).

Article PubMed Google Scholar

Herrick, A. L. et al. A double-blind, randomized, placebo-controlled crossover trial of the 2c-adrenoceptor antagonist orm-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology 53, 948952 (2014).

Article CAS PubMed Google Scholar

Gyires, K., Zdori, Z. S., Trk, T. & Mtyus, P. 2-Adrenoceptor subtypes-mediated physiological, pharmacological actions. Neurochem. Int. 55, 447453 (2009).

Article CAS PubMed Google Scholar

Hunter, J. C. et al. Assessment of the role of 2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br. J. Pharmacol. 122, 13391344 (1997).

Article CAS PubMed PubMed Central Google Scholar

Cooke, J. P. et al. Role of digital artery adrenoceptors in Raynauds disease. Vasc. Med. 2, 17 (1997).

Article CAS PubMed Google Scholar

Freedman, R. R., Baer, R. P. & Mayes, M. D. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynauds disease. Circulation 92, 14481451 (1995).

Article CAS PubMed Google Scholar

Johnson, S., Iazzetta, J. & Dewar, C. Severe Raynauds phenomenon with Yohimbine therapy for erectile dysfunction. J. Rheumatol. 30, 25032505 (2003).

PubMed Google Scholar

Sandler, B. & Aronson, P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology 41, 343345 (1993).

Article CAS PubMed Google Scholar

Varadi, D. P. & Lawrence, A. M. Suppression of Raynauds phenomenon by methyldopa. Arch. Intern. Med. 124, 1318 (1969).

Article CAS PubMed Google Scholar

Guo, X. et al. Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. Oncogene 29, 39083920 (2010).

Article CAS PubMed Google Scholar

Gomez, I., Foudi, N., Longrois, D. & Norel, X. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot. Essent. Fat. Acids 89, 5563 (2013).

Article CAS Google Scholar

Ren, J., Karpinski, E. & Benishin, C. G. Prostaglandin E2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery. J. Pharmacol. Exp. Ther. 275, 710719 (1995).

CAS PubMed Google Scholar

Marceau, F. & Regoli, D. Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discov. 3, 845852 (2004).

Article CAS PubMed Google Scholar

Freedman, R. R., Girgis, R. & Mayes, M. D. Abnormal responses to endothelial agonists in Raynauds phenomenon and scleroderma. J. Rheumatol. 28, 119121 (2001).

CAS PubMed Google Scholar

Bedarida, G., Kim, D., Blaschke, T. F. & Hoffman, B. B. Venodilation in Raynauds disease. Lancet (Lond., Engl.) 342, 14511454 (1993).

Article CAS Google Scholar

Rosengren, A. H. et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 327, 217220 (2010).

Article ADS CAS PubMed Google Scholar

Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 52, 680691 (2020).

Article CAS PubMed PubMed Central Google Scholar

Morrison, S. F. Differential control of sympathetic outflow. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R683R698 (2001).

Article ADS CAS PubMed Google Scholar

Carnovale, C. et al. Beta-blocker-associated hypoglycaemia: new insights from a real-world pharmacovigilance study. Br. J. Clin. Pharmacol. 87, 33203331 (2021).

Article CAS PubMed Google Scholar

Gamazon, E. R. et al. Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nat. Genet. 50, 956967 (2018).

Article CAS PubMed PubMed Central Google Scholar

View original post here:
ADRA2A and IRX1 are putative risk genes for Raynauds ... - Nature.com